Dolomite, a manufacturer of microfluidic systems and devices, has developed a novel droplet merger chip with GigaGen of San Francisco, CA for massively parallel single cell genetic analysis.
Measuring 15mm x 22.5mm, the glass microfluidic chip facilitates fast and consistent merging of two individual droplet streams, benefiting a range of applications including DNA amplification, biochemical analysis, single cell analysis and high throughput experimentation. Unlike other methods, which incorporate expensive and bulky high voltage electronics to merge droplets using electrostatic forces, the droplet merger chip works by simply “squeezing” droplets together in a carefully designed merging chamber.
Dolomite says the result is a unique microfluidic device, which points the way to low cost disposable chips in future versions.
‘A simple and reliable droplet merging technology is an important step forward for us,’ said David Johnson, chief executive and founder of GigaGen. ‘We are now using these chips in our system for massively parallel single cell genetic analysis.’
GigaGen has filed a patent application describing the chip design and its applications in the field of genetic analysis of cells.
As part of a licensing agreement with GigaGen, Dolomite will be offering the technology later this year to researchers in academia and commercial users in a wide range of application areas.
‘Many of our customers have asked us for chips to create droplets, merge them, and then carry out further processing and analysis,’ said Andrew Lovatt, chief executive of Dolomite.
‘Our partnership with Sphere Fluidics gives us additional capability in selecting the surfactants we use, to optimise droplet behaviour and stability under a wide range of temperature and biological conditions.’
Dolomite and GigaGen develop droplet merging technology
For use in massively parallel single cell genetic analysis
You may also like
Trending Articles
You may also like
Manufacturing
Dolomite and Lab on a Chip launch Productizing Science Competition 2015
Dolomite and Lab on a Chip are challenging entrepreneurial researchers, scientists and engineers to enter the Productizing Science Competition 2015, proposing novel, microfluidics-based concepts with commercial potential
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Research & Development
Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi
The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites